B
Bull
Bull · 25%SUPN
$33.77
Scenario price
$37.880
-1.617 (-4.27%)At close
Loading chart…
- High
- 39.500
- Open
- 39.490
- VWAP
- 38.31
- Volume
- 1.44M
- Mkt Cap
- 1.48B
- Low
- 37.540
- Amount
- 55.22M
- EV/EBITDA, TTM
- 30.50
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
AI analysis of Supernus Pharmaceuticals Inc (SUPN)
HoldSupernus Pharmaceuticals Inc is currently not a strong buy due to significant recent losses and negative technical indicators. The current price is $37.88, and the stock has a 5-day change of -11.23%. Additionally, the RSI is extremely low at 13.38, indicating oversold conditions, but this also suggests potential for a rebound. However, the company reported a net loss exceeding $58 million in Q2 2026, contrasting sharply with a net income of $22.5 million in Q2 2025, highlighting ongoing financial struggles. The main risk is the insider selling, which increased by 2510.70% over the last month, signaling a lack of confidence among insiders. Therefore, while the stock may have potential long-term upside due to the merger with Indivior, the current financial and technical indicators suggest a hold position for now.
Analyst Ratings (8)
+61.91% upside
Buy
6 Buy
2 Hold
0 Sell
Current: 37.88
Low
55.00
Average
61.33
High
65.00
Cantor Fitzgerald
Overweight
$67
2026-07-09
Cantor Fitzgerald
2026-07-09
Price Target
$67
Overweight
TD Cowen
Buy
$65
2026-02-25
TD Cowen
2026-02-25
Price Target
$65
Buy
Stifel
Hold
$55
2025-12-19
Stifel
2025-12-19
Price Target
$55
Hold
TD Cowen
Buy
$60
2025-10-23
TD Cowen
2025-10-23
Price Target
$60
Buy
Cantor Fitzgerald
Overweight
$63
2025-09-30
Cantor Fitzgerald
2025-09-30
Price Target
$63
Overweight
Valuation Metrics
The current forward P/E ratio for Supernus Pharmaceuticals Inc (SUPN) is 20.16, compared to its 5-year average forward P/E of 20.52.
Alphio AI Price Scenarios for SUPN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SUPN
Events Timeline
News
7.009-25PRnewswireInvestor Rights Law Firm Investigates Multiple Companies
1.009-02NewsfilterSupernus Pharmaceuticals Announces September Investor Conference Participation
- 8.508-31Newsfilter
Chloe Kim Partners with Supernus to Advocate ADHD Awareness and Treatment
7.008-07PRnewswireInvestor Rights Law Firm Investigates Multiple Companies
8.508-03FoolSupernus Pharmaceuticals Announces Merger with Indivior
SUPN FAQ — answered by Alphio AI
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Supernus Pharmaceuticals Inc is currently not a strong buy due to significant recent losses and negative technical indicators. The current price is $37.88, and the stock has a 5-day change of -11.23%. Additionally, the RSI is extremely low at 13.38, indicating oversold conditions, but this also suggests potential for a rebound. However, the company reported a net loss exceeding $58 million in Q2 2026, contrasting sharply with a net income of $22.5 million in Q2 2025, highlighting ongoing financial struggles. The main risk is the insider selling, which increased by 2510.70% over the last month, signaling a lack of confidence among insiders. Therefore, while the stock may have potential long-term upside due to the merger with Indivior, the current financial and technical indicators suggest a hold position for now.
8 analysts cover SUPN: 6 rate it Buy, 2 Hold and 0 Sell. The average price target is 61.33.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.